Asset Details
Do you wish to reserve the book?
Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study
Do you wish to request the book?
Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study
2023
Overview
Background
Currently, the main pharmaceutical intervention for COVID-19 is vaccination. While antidepressant (AD) drugs have shown some efficacy in treatment of symptomatic COVID-19, their preventative potential remains largely unexplored. Analysis of association between prescription of ADs and COVID-19 incidence in the population would be beneficial for assessing the utility of ADs in COVID-19 prevention.
Methods
Retrospective study of association between AD prescription and COVID-19 diagnosis was performed in a cohort of community-dwelling adult mental health outpatients during the 1st wave of COVID-19 pandemic in the UK. Clinical record interactive search (CRIS) was performed for mentions of ADs within 3 months preceding admission to inpatient care of the South London and Maudsley (SLaM) NHS Foundation Trust. Incidence of positive COVID-19 tests upon admission and during inpatient treatment was the primary outcome measure.
Results
AD mention was associated with approximately 40% lower incidence of positive COVID-19 test results when adjusted for socioeconomic parameters and physical health. This association was also observed for prescription of ADs of the selective serotonin reuptake inhibitor (SSRI) class.
Conclusions
This preliminary study suggests that ADs, and SSRIs in particular, may be of benefit for preventing COVID-19 infection spread in the community. The key limitations of the study are its retrospective nature and the focus on a mental health patient cohort. A more definitive assessment of AD and SSRI preventative potential warrants prospective studies in the wider demographic.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Aged
/ Antidepressive Agents - therapeutic use
/ Antigens
/ Complications and side effects
/ COVID-19
/ COVID-19 - prevention & control
/ Drug use
/ Female
/ Humans
/ Male
/ Medicine
/ Mental Disorders - drug therapy
/ Outpatients - statistics & numerical data
/ Prescription Drugs - therapeutic use
/ Selective Serotonin Reuptake Inhibitors - therapeutic use
/ Severe acute respiratory syndrome coronavirus 2
/ SSRI
